|
|
| | TEMAFLOXACIN HYDROCHLORIDE Basic information |
| Product Name: | TEMAFLOXACIN HYDROCHLORIDE | | Synonyms: | TEMAFLOXACIN HYDROCHLORIDE;1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-Quinolinecarboxylic acid hydrochloride;Abbott 62254;3-Quinolinecarboxylicacid,1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-,hydrochloride (1:1);1-(2,4-Difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride | | CAS: | 105784-61-0 | | MF: | C21H18F3N3O3.ClH | | MW: | 453.846 | | EINECS: | | | Product Categories: | | | Mol File: | 105784-61-0.mol |  |
| | TEMAFLOXACIN HYDROCHLORIDE Chemical Properties |
| storage temp. | Sealed in dry,Room Temperature | | solubility | ≤2mg/ml in DMSO;5mg/ml in dimethyl formamide | | form | crystalline solid |
| | TEMAFLOXACIN HYDROCHLORIDE Usage And Synthesis |
| Description | Temafloxacin hydrochloride is a new fluoroquinolone antibacterial structurally and
mechanistically related to tosufloxacin, another microbial DNA topoisomerase
inhibitor introduced in 1990. It is particularly useful against beta-lactamase producing
organisms and is indicated for the treatment of respiratory and urinary tract infections
as well as sexually transmitted diseases, skin and soft tissue infections. The compound
has high tissue penetration and is reported to have a low propensity to cause adverse
effects and drug interactions. | | Originator | Abbott (U.S.A.) | | Uses | Temafloxacin Hydrochloride is an antimicrobial quinolone drug. | | Uses | Antibacterial (microbial DNA topoisomerase
inhibitor). | | Brand name | Omniflox (Abbott);Temac. | | in vitro | the in-vitro activities of temafloxacin, ciprofloxacin, and ofloxacin against gram-negative bacteria were compared. the 90% minimal inhibitory concentrations (mic90s) of temafloxacin for respiratory pathogens were less than or equal to 0.06 micrograms/ml. temafloxacin was also active against bacterial agents of sexually transmitted diseases, such as neisseria gonorrhoeae and chlamydia trachomatis [1]. | | in vivo | mixed aerobic-anaerobic infection was induced by i.p. implantation of gelatin capsules containing bacteroides fragilis, escherichia coli, and sterile rat faeces. temafloxacin was found to be highly active with a 90.9% cure rate in comparison with no treatment, and as active as a combination of clindamycin and gentamicin. temafloxacin at 12 mg/dose resulted in rise to serum concentrations exceeding the mic values of both microorganisms for at least 8 h [2]. | | references | [1] hardy dj. in vitro activity of temafloxacin against gram-negative bacteria: an overview. am j med. 1991 dec 30;91(6a):19s-23s.
[2] thadepalli h, hajji m, perumal vk, chuah sk, gollapudi s. evaluation of temafloxacin in a rat model of intra-abdominal abscess. j antimicrob chemother. 1992 jun;29(6):687-92.
[3] ball p. the role of temafloxacin in the community setting: an overview. j antimicrob chemother. 1991 dec;28 suppl c:121-30. |
| | TEMAFLOXACIN HYDROCHLORIDE Preparation Products And Raw materials |
|